We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Commercial Availability of Lutetium-177

By Biotechdaily staff writers
Posted on 06 Nov 2002
Lutetium-177 (Lu-177), an important radioisotope being investigated for use in the radiotherapeutic treatment of cancers such as breast, prostate, colon and brain, is now commercially available from PerkinElmer Life Sciences (Boston, MA, USA).

PerkinElmer says it is the first company with worldwide distribution capabilities to offer Lu-177. More...
Until now, there has been no reliable supplier of this important radioisotope. Demand for Lu-177 is increasing, and the current commercial supply is limited. PerkinElmer's goal is to provide the market with a much-needed continuous and reliable supply. The company's broad distribution channels are geared to help ensure timely, quality delivery of this short-lived isotope. The product is available for research use only.

PerkinElmer is committed to accelerating the market development for this important radioisotope, which could lead to another treatment for cancer,” said Paul Gillyon, vice president and general manager of research products at PerkinElmer Life Sciences. "By making radionuclides like lutetium-177 and yttrium-90 available commercially, we believe we can support and impact research that will lead to newer and better therapeutic alternatives.”




Related Links:
PerkinElmer

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.